Emcure Pharmaceuticals Ltd banner
E

Emcure Pharmaceuticals Ltd
NSE:EMCURE

Watchlist Manager
Emcure Pharmaceuticals Ltd
NSE:EMCURE
Watchlist
Price: 1 668.9 INR -0.19%
Market Cap: ₹316.4B

Emcure Pharmaceuticals Ltd
Depreciation & Amortization

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Emcure Pharmaceuticals Ltd
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
E
Emcure Pharmaceuticals Ltd
NSE:EMCURE
Depreciation & Amortization
₹3.8B
CAGR 3-Years
16%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Depreciation & Amortization
₹19.1B
CAGR 3-Years
17%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Depreciation & Amortization
₹11.4B
CAGR 3-Years
1%
CAGR 5-Years
0%
CAGR 10-Years
N/A
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Depreciation & Amortization
₹27.2B
CAGR 3-Years
6%
CAGR 5-Years
5%
CAGR 10-Years
N/A
Lupin Ltd
NSE:LUPIN
Depreciation & Amortization
₹12.8B
CAGR 3-Years
11%
CAGR 5-Years
6%
CAGR 10-Years
N/A
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Depreciation & Amortization
₹8B
CAGR 3-Years
8%
CAGR 5-Years
4%
CAGR 10-Years
N/A
No Stocks Found

Emcure Pharmaceuticals Ltd
Glance View

Market Cap
316.4B INR
Industry
Pharmaceuticals

Emcure Pharmaceuticals Ltd. emerged as a prominent player in the Indian pharmaceutical landscape, guided by a commitment to innovation and accessibility. Founded in 1981 by Satish Mehta, the company started as a small-scale manufacturer and has since evolved into a global pharmaceutical powerhouse. Emcure thrives on a multifaceted business model that encompasses the complete pharmaceutical value chain, from research and development to manufacturing and distribution. The company's success rests on its robust portfolio of generics, branded generics, and biopharmaceuticals, which cater to diverse therapeutic areas like cardiology, oncology, gynecology, and infectious diseases. The driving force behind Emcure's financial engine is its ability to balance volume and value. Through a network of state-of-the-art facilities, Emcure sustains a strong presence both domestically and internationally, with exports spanning over 70 countries. The firm capitalizes on economies of scale by leveraging its extensive production infrastructure, allowing it to offer high-quality medications at competitive prices. Furthermore, strategic collaborations and licensing agreements empower Emcure to penetrate new markets and broaden its product offerings. By continually expanding its pipeline and embracing cutting-edge technologies, Emcure not only secures its position in the competitive pharmaceutical industry but also reinforces its mission to deliver affordable healthcare solutions globally.

EMCURE Intrinsic Value
1 191.56 INR
Overvaluation 29%
Intrinsic Value
Price ₹1 668.9
E

See Also

What is Emcure Pharmaceuticals Ltd's Depreciation & Amortization?
Depreciation & Amortization
3.8B INR

Based on the financial report for Mar 31, 2025, Emcure Pharmaceuticals Ltd's Depreciation & Amortization amounts to 3.8B INR.

What is Emcure Pharmaceuticals Ltd's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 3Y
16%

Over the last year, the Depreciation & Amortization growth was 23%. The average annual Depreciation & Amortization growth rates for Emcure Pharmaceuticals Ltd have been 16% over the past three years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett